Search Results for: Rhythm Announces Preliminary Data from
Articles
November 6, 2017
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome November 6, 2017
Rhythm Pharmaceuticals, Inc. recently announced the presentation of preliminary data from an ongoing Phase 2 proof-of-concept study evaluating the safety...
November 1, 2022
Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity November 1, 2022
Rhythm Pharmaceuticals, Inc. recently announced that setmelanotide received Breakthrough Therapy Designation from the US FDA for the treatment of hypothalamic...
